Provider review
Livbetr review
By The Dose Brief Desk · Updated
Livbetr’s fall promotion combines low monthly headlines with four-week shipments and a continuous-plan discount. Clarify the commitment before comparing costs.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- Fall offer from $65/month; complete term unconfirmed
- Tirzepatide
- Fall offer from $110/month; complete term unconfirmed
- Availability
- Confirm selected-product eligibility in your state.
- Treatment formats
- Compounded semaglutide and tirzepatide treatment.
Promotion mentions a continuous plan and four-week shipments; billing cadence and full commitment need confirmation.
The promotional amount is not the whole contract
Livbetr advertises a fall offer starting at $65 a month for semaglutide and $110 for tirzepatide, alongside a $200 continuous-plan discount. The reviewed homepage does not establish a complete payment schedule behind those headlines. Obtain the amount due now and the total required to keep the discounted rate.
Shipments and billing may use different calendars
The site describes medication arriving every four weeks. Ask whether charges also recur every four weeks or on calendar-month dates. That distinction affects both the annual budget and how early a patient must stop the next shipment.
Included services and dose pricing
Livbetr describes clinical review, included shipping and pricing that does not increase simply with the prescribed dose. Those features should be confirmed for the specific promotion and formulation. A starting offer does not establish that every patient or state qualifies.
What to verify before enrolling
The site identifies Livbetr LLC and describes independent clinical and pharmacy services, but the assigned prescriber and pharmacy were not established here. Ask for those names and for the continuous-plan cancellation and refund rules. The low headline alone is insufficient to judge the offer’s flexibility.
What stands out
- Separates semaglutide and tirzepatide starting offers
- Advertises included delivery and dose-flat pricing
What to check
- Continuous-plan obligation is unresolved
- Four-week shipment and monthly pricing language need reconciliation
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.